quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:03:29·2d
SECFiling
Ligand Pharmaceuticals Incorporated logo

SEC Form DEFA14A filed by Ligand Pharmaceuticals Incorporated

LGND· Ligand Pharmaceuticals Incorporated
Health Care
Original source

Companies

  • LGND
    Ligand Pharmaceuticals Incorporated
    Health Care

Recent analyst ratings

  • Mar 11UpdateBofA Securities$244.00
  • Dec 9UpdateCitigroup$270.00
  • Apr 10UpdateStifel$143.00
  • Oct 3UpdateOppenheimer$135.00
  • Jul 30UpdateRBC Capital Mkts$130.00
  • Feb 22UpdateBenchmark$130.00

Related

  • PR2d
    Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
  • SEC2d
    SEC Form DEF 14A filed by Ligand Pharmaceuticals Incorporated
  • PR10d
    Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
  • INSIDER21d
    SEC Form 4 filed by Kozarich John W
  • INSIDER21d
    SEC Form 4 filed by Reardon Andrew
  • SEC22d
    SEC Form 144 filed by Ligand Pharmaceuticals Incorporated
  • INSIDER23d
    SEC Form 4 filed by Lamattina John L
  • INSIDER27d
    SEC Form 4 filed by Espinoza Octavio
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022